Please find attached intimation under Regulation 30 of SEBI (LODR) Regualtions, 2015
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mankind Pharma's Board approved FY2026 audited results showing standalone revenue of ₹10,421 Crores (up 9.6% from ₹9,507 Crores in FY2025) and profit after tax of ₹713.61 Crores, representing strong PAT growth from ₹421.74 Crores in prior year. Q4 FY2026 standalone revenue was ₹2,581.82 Crores with net profit margin of 28% (vs 11% in Q4 FY2025) and operating margin of 35% (vs 16% in Q4 FY2025). The Board approved ₹500 Crores additional investment in subsidiary Mankind Medicare Private Limited and realigned NCD security cover post ₹1,250 Crores redemption. Executive Directors (Chairman, Vice Chairman & MD, CEO) voluntarily waived commission for FY2025-26 to strengthen cash position. Joint statutory auditors issued unmodified opinion. Prior year figures have been restated due to BSV Women's Health Portfolio acquisition. Income tax proceedings with ₹1,866.69 Crores demand remain pending in appeal.
Strong financial performance with improved profitability margins. Executive commission waiver signals confidence in cash flow. Pending tax litigation remains a contingent liability. Auditor emphasis on income tax matter (not a qualification) indicates ongoing uncertainty.